•
Jun 30, 2023

biote Q2 2023 Earnings Report

Reported solid revenue growth and continued progress optimizing capital structure.

Key Takeaways

Biote reported a 19.1% increase in revenue, reaching $49.3 million, driven by procedure and dietary supplement revenue growth. The company's gross profit margin increased by 60 basis points to 67.9%. Net loss was $(13.1) million, with a GAAP loss per share of $(0.25). Adjusted EBITDA increased by 10.6% to $14.5 million.

Revenue increased by 19.1% to $49.3 million.

Gross profit margin increased by 60 basis points to 67.9%.

Net loss was $(13.1) million, with a GAAP loss per share of $(0.25).

Adjusted EBITDA increased by 10.6% to $14.5 million.

Total Revenue
$49.3M
Previous year: $27.8M
+77.0%
EPS
-$0.25
Previous year: -$0.34
-26.5%
Gross Profit Margin
67.9%
Gross Profit
$33.4M
Previous year: $27.8M
+20.2%
Cash and Equivalents
$68.5M
Free Cash Flow
$6.77M
Previous year: -$28.6M
-123.6%
Total Assets
$139M
Previous year: $115M
+20.6%

biote

biote

Forward Guidance

Biote anticipates a more moderate pace of growth in the second half of 2023 due to temporary inefficiencies from sales realignment and evolving market dynamics. As a result, the company forecasts 2023 revenue and Adjusted EBITDA will likely be toward the lower end of their guidance range.